Text Size

A Randomized Controlled Trial of Laparoscopic Nissen Fundoplication Treatment of Patients With Chronic GERD

This study has been completed.
Sponsor:
Collaborator:
St. Joseph's Healthcare Hamilton
Information provided by (Responsible Party):
Mehran Anvari, McMaster University
ClinicalTrials.gov Identifier:
NCT00182260
First received: September 12, 2005
Last updated: November 14, 2012
Last verified: November 2012
History of Changes
  Purpose

LNF is an effective intervention in the management of patients with chronic GERD requiring maintenance therapy. LNF is cost-effective compared with long-term medical therapy.

LNF is more effective than maximum medical therapy in control of respiratory symptoms and complications of GERD.


Condition Intervention
Gastroesophageal Reflux
 Drug: Proton Pump Inhibitors
Procedure: Laparoscopic Nissen Fundoplication

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: ELVIS (Esophagitis-Laparoscopy Versus Inhibitors of Secretion) A Randomized Controlled Trial of Laparoscopic Nissen Fundoplication (LNF) Versus Omeprazole for Treatment of Patients With Chronic Gastro-Esophageal Reflux Disease (GERD)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by McMaster University:

Primary Outcome Measures:
  • GERD Symptom Scale
  • Symptom-free Day Measurement
  • Cost Measurement

Secondary Outcome Measures:
  • 24-hour pH
  • Economic Analysis
  • Endoscopy
  • Esophageal manometry
  • Health related quality of life (SF-36)
  • Health Utility Index
  • Respiratory function, airways hypersensitivity and inflammation and microaspiration

Enrollment: 216
Study Start Date: January 2000
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Proton Pump Inhibitor
Patients randomized to medical therapy received optimized treatment with PPI using a standardized management protocol based on best evidence and published guidelines.
 Drug: Proton Pump Inhibitors
Active Comparator: Laparoscopic Nissen Fundoplication
Surgical patients underwent LNF using previously published technique.
 Procedure: Laparoscopic Nissen Fundoplication

Detailed Description:

GERD encompasses a variety of symptoms and pathological findings caused by the reflux of gastric contents into the esophagus although symptoms and pathology may occur independently of each other. GERD usually presents with typical symptoms of retrosternal burning (heartburn) with or without chest pain and regurgitation of gastric contents into the back of the mouth. However, symptoms often occur in the absence of abnormalities associated with GERD, such as esophageal erosions, ulceration, stricturing or Barrett's esophagus. There is no clear correlation between symptoms and the histological features of GERD. Less prevalent manifestations of GERD include the geneses of dental erosions and respiratory disease including aspiration pneumonia, asthma, chronic laryngitis. Most often, GERD is due to excessive reflux of gastric contents into the esophagus rather than gastric acid hypersecretion. Reflux is caused by an increase in the frequency of inappropriate transient relaxations of the lower esophageal sphincter (LES). In most patients, basal resting LES pressure is normal although LES hypotonia, reduced esophageal body contractility and the presence of a hiatus hernia may exacerbate reflux or reduce esophageal clearance. Impaired esophageal mucosal resistance can increase the potential for esophageal damage. Bile acids and pancreatic enzymes have been implicated in the pathogenesis of GERD but it is generally accepted that the major causes of esophageal symptoms and injury are gastric acid and pepsin, which are active only at low ambient pH. Severity of esophagitis and of reflux symptoms correlate well with the duration of esophageal acid exposure with clear correlation between acid secretory inhibition and esophagitis healing rates for any given drug. On this basis, treatment for GERD has been directed towards:

Minimization of potential precipitating factors by lifestyle modifications such as weight loss, small meals and, avoidance of alcohol and tobacco.

Improving LES pressure, esophageal clearance and gastric emptying, using prokinetic agents.

Neutralization of acid in the stomach or esophagus, using antacids. Reduction of acid secretion, using histamine receptor antagonists(H2RAs) or PPI's.

Surgical prevention of gastro-esophageal reflux by fundoplication. In practice, the latter two approaches are the most successful for patients with more severe GERD and PPI's have proven more efficacious than H2RAs.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female GERD patients aged 18-70 years with GERD symptoms.
  • Prior long-term treatment with PPI with minimum duration of 1 year with expected future duration of at least 2 more years.
  • Controlled on 20-40mg/day maintenance PPI therapy prior to study, defined as GERD symptom score<18 and score of 70 or more on 1-100 Global Rating Scale at screening (on medication).
  • Increase in GERD symptom score>=15 points at baseline (off omeprazole).
  • GERD symptom score>=18 at baseline (off omeprazole).
  • Percent acid reflux in 24hr 4% at baseline (off omeprazole).
  • Positive Bernstein test at baseline.
  • Willingness to adhere to randomized treatment with availability for 3 years of follow-up.
  • Ability to answer self and interviewer-administered questions in English.
  • Signed informed consent.

Exclusion Criteria:

  • Aperistaltic esophagus.
  • Severe cardiac, respiratory, hematologic or other disease constituting an unacceptable surgical risk in the investigator's opinion.
  • Previous gastric, esophageal or anti-reflux surgery.
  • History of malignancy within the last year with the exception of basal cell carcinoma.
  • Pregnancy or an intention to become pregnant in the following year.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00182260

Locations
Canada, Ontario
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada, L8N 4A6
Sponsors and Collaborators
McMaster University
St. Joseph's Healthcare Hamilton
Investigators
Principal Investigator: Mehran Anvari, MB, BS, PhD McMaster University
Principal Investigator: David Armstrong, MB, BCh, MA McMaster University
Principal Investigator: Charles H. Goldsmith, PhD McMaster University
  More Information

No publications provided

Responsible Party: Mehran Anvari, Principal Investigator, McMaster University
ClinicalTrials.gov Identifier: NCT00182260     History of Changes
Other Study ID Numbers: CIHR-MCT-38147, MOH Grant 05276
Study First Received: September 12, 2005
Last Updated: November 14, 2012
Health Authority: Canada: Canadian Institutes of Health Research
Canada: Ministry of Health and Long-Term Care Research

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
 Digestive System Diseases
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 21, 2013